More importantly, combined treatment of anti-PD-1/GITR mAb andchemotherapeutic drugs (cisplatin or paclitaxel) further increased the antitumorefficacy with 80% of mice obtaining tumor-free long-term survival in murine ID8ovarian cancer and 4 T1 breast cancer models. Here, TNFRSF18 is linked to breast carcinoma.